Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

CC, Parker; RE, Coleman; O, Sartor; NJ, Vogelzang; D, Bottomley; D, Heinrich; SI, Helle; JM, O'Sullivan; SD, Fosså; A, Chodacki; P, Wiechno; J, Logue; M, Seke; A, Widmark; DC, Johannessen; P, Hoskin; ND, James; A, Solberg; I, Syndikus; J, Kliment; S, Wedel; S, Boehmer; M, Dall'Oglio; L, Franzén; ØS, Bruland; O, Petrenciuc; K, Staudacher; R, Li; S, Nilsson

doi:10.1016/j.eururo.2017.06.021

Public

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

Shared by NobleBlocks on Jul 11, 2017 • 12:00 AM UTC

Authors:

Parker CC

Coleman RE

Sartor O

Abstract

Background In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-223 monitoring underlies a comprehensive safety and...

Subject

Follow-up

Bone Metastases

Castration-resistant Prostate Cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!